The battle-tested biotech exec Tom Hughes is headed back to a CEO post.
After leading Zafgen through an IPO, a savage safety crisis and a complete revamp, Hughes stepped down from the CEO role at Zafgen several months ago to take the chief scientific officer’s job as Jeffrey Hatfield was named CEO. Now he’s relocating to another Cambridge/Boston biotech outfit called Navitor, which has just launched its first early-stage clinical study to test the anti-aging theories it’s been working on for the past 4 years.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription